Evidence check: CYP2D6 in the context of fatigue

The provided context contains no direct evidence linking CYP2D6 to fatigue. CYP2D6 is a drug-metabolizing enzyme that affects the breakdown of many medications (e.g., antidepressants, beta-blockers, opioids). Indirectly, altered enzyme activity (poor, intermediate, extensive, or ultrarapid metabolizer) may influence drug efficacy or side effects – including fatigue as an adverse reaction. However, this is a pharmacogenetic effect, not a direct genetic cause of fatigue. Evidence for an independent role of CYP2D6 in fatigue without medication is weak and based on mechanistic reasoning, not clinical studies from the given context. MyBody-X tests for CYP2D6 would thus be screening tools for drug tolerance, not diagnostic for fatigue. Their utility is limited because many factors (medication, lifestyle, other genes) contribute. Persistent fatigue requires medical evaluation. Evidence grade: unclear/mechanistic.